Zobrazeno 1 - 10
of 337
pro vyhledávání: '"L. Rothenberg"'
Autor:
Robert J. Coffey, John C. Gore, Darryl J. Bornhop, Mace L. Rothenberg, Ronald M. Baldwin, M. Sib Ansari, Todd E. Peterson, Mohammed Noor Tantawy, Bonnie LaFleur, M. Kay Washington, Nathan J. Mutic, Jingping Xie, Eliot T. McKinley, Chirayu Shah, Shelby K. Wyatt, John M. Virostko, A. Coe Foutch, Nipun B. Merchant, H. Charles Manning
Purpose: To evaluate noninvasive molecular imaging methods as correlative biomarkers of therapeutic efficacy of cetuximab in human colorectal cancer cell line xenografts grown in athymic nude mice. The correlation between molecular imaging and immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447b9a40084e020ea7db55de79154c60
https://doi.org/10.1158/1078-0432.c.6517170
https://doi.org/10.1158/1078-0432.c.6517170
Autor:
Robert J. Coffey, John C. Gore, Darryl J. Bornhop, Mace L. Rothenberg, Ronald M. Baldwin, M. Sib Ansari, Todd E. Peterson, Mohammed Noor Tantawy, Bonnie LaFleur, M. Kay Washington, Nathan J. Mutic, Jingping Xie, Eliot T. McKinley, Chirayu Shah, Shelby K. Wyatt, John M. Virostko, A. Coe Foutch, Nipun B. Merchant, H. Charles Manning
Supplementary Figures S1-S4 from Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d3b5f977abfcdeb72512ec0826fd3d
https://doi.org/10.1158/1078-0432.22439745
https://doi.org/10.1158/1078-0432.22439745
Autor:
Mace L. Rothenberg, Jordan D. Berlin, John A. Hartley, Chih-Yi Liao, Victoria J. Spanswick, Wendy L. Vermeulen, David L. Hachey, M. Wade Calcutt, Alice P. Chen, Wooin Lee, Igor Puzanov
Supplementary Figures S1-S2; Supplementary Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b33f7dc6d4b5b33f301b098ec83fff
https://doi.org/10.1158/1078-0432.22442820
https://doi.org/10.1158/1078-0432.22442820
Autor:
Mace L. Rothenberg, Jordan D. Berlin, John A. Hartley, Chih-Yi Liao, Victoria J. Spanswick, Wendy L. Vermeulen, David L. Hachey, M. Wade Calcutt, Alice P. Chen, Wooin Lee, Igor Puzanov
Purpose: This phase I study assessed the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SJG-136, a sequence-specific DNA cross-linking agent, in patients with advanced cancer.Experimental Desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bb5972f54cb43497270d4bd56717e6c
https://doi.org/10.1158/1078-0432.c.6519480
https://doi.org/10.1158/1078-0432.c.6519480
Autor:
Dae Hyun Kim, Lee-Jen Wei, Bo Huang, Mace L. Rothenberg, Enayet Talukder, Wanling Xie, Xiaodong Luo, Toni K. Choueiri, Lu Tian, Zachary R. McCaw
Publikováno v:
Ann Intern Med
In comparative studies, the treatment effect is often assessed using a binary outcome that indicates response to the therapy. Commonly used summary measures for response include the cumulative and the current response rate at a specific time point. T
Autor:
Peter J O’Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg, et al
Publikováno v:
Biologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 563-569 (2008)
Peter J O’Brien1, Rajeev Ramanathan2, Jonathan M Yingling1, Jose Baselga3, Mace L Rothenberg4, Michael Carducci5, Thomas Daly1, Dorothy Adcock2, Michael Lahn11Eli Lilly and Company Research Laboratories, Lilly Corporate Center, Indianapolis, IN, US
Externí odkaz:
https://doaj.org/article/eb6a465b749d4abc800f350f26a9a6fa
Autor:
Kerry L. Reynolds, Elad Sharon, Meghan E. Sise, Douglas B. Johnson, Laura A. Petrillo, William C Louv, Mace L. Rothenberg, Michael Dougan, Sean Khozin, Aakanksha Khandelwal, Teilo H Schaller, Amanda C. Guidon, Shaily Arora, Ravikumar Komandur Elayavilli, Osama E. Rahma, Alexandra-Chloé Villani, Leyre Zubiri
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use o
Autor:
Nadine J McCleary, William S Harmsen, Ellana Haakenstad, James M Cleary, Jeffrey A Meyerhardt, John Zalcberg, Richard Adams, Axel Grothey, Alberto F Sobrero, Eric Van Cutsem, Richard M Goldberg, Marc Peeters, Josep Tabernero, Matt Seymour, Leonard B Saltz, Bruce J Giantonio, Dirk Arnold, Mace L Rothenberg, Miriam Koopman, Hans-Joachim Schmoll, Henry C Pitot, Paulo M Hoff, Niall Tebbutt, Gianluca Masi, John Souglakos, Carsten Bokemeyer, Volker Heinemann, Takayuki Yoshino, Benoist Chibaudel, Aimery deGramont, Qian Shi, Stuart M Lichtman
Publikováno v:
JNCI Cancer Spectrum
Scientia
Scientia
Background We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials.
Autor:
Hans-Joachim Schmoll, Eric Van Cutsem, Bruce J. Giantonio, Richard M. Goldberg, Matthew T. Seymour, Niall C. Tebbutt, Qian Shi, Josep Tabernero, Dirk Arnold, Mace L. Rothenberg, Richard Adams, John Souglakos, Jeffrey A. Meyerhardt, Takayuki Yoshino, Benoist Chibaudel, Carsten Bokemeyer, Henry C. Pitot, Nadine Jackson McCleary, Gianluca Masi, Volker Heinemann, Paulo M. Hoff, William S. Harmsen, Ellana Haakenstad, John Zalcberg, Leonard B. Saltz, Stuart M. Lichtman, Aimery deGramont, Marc Peeters, Axel Grothey, Alberto Sobrero, James M. Cleary, Miriam Koopman
Publikováno v:
SSRN Electronic Journal.
Background: We evaluated the time to progression and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared to adults aged less than 70 years following progression on first-line clinica
Publikováno v:
Cancer journal (Sudbury, Mass.). 26(4)
More than 1.8 million cancer diagnoses will be made in 2020 driving substantial health and economic burden for patients. The financial impact of out-of-pocket payments for hospital stays, outpatient services, physician appointments, and prescription